- cIAP1 (cellular Inhibitor of Apoptosis Protein 1) is a multifunctional signalling protein belonging to the IAP family, where it works alongside cIAP2 and XIAP to regulate apoptosis, ubiquitination and inflammatory signalling. Unlike XIAP, which directly inhibits caspases, cIAP1 primarily controls cell fate through its ubiquitin ligase activity. This makes cIAP1 a central checkpoint in TNF receptor signalling, determining whether a cell activates NF‑κB survival pathways or switches into apoptosis or necroptosis.
- cIAP1 contains three BIR (Baculovirus IAP Repeat) domains and a C‑terminal RING finger domain. The BIR domains mediate interactions with signalling proteins such as TRAF2, while the RING domain functions as an E3 ubiquitin ligase. Through this ligase activity, cIAP1 assembles K63‑linked ubiquitin chains on RIPK1, a key adaptor in TNF receptor signalling. These ubiquitin chains stabilise the pro‑survival signalling complex that activates canonical and non‑canonical NF‑κB pathways. As long as cIAP1 is present and active, TNF stimulation leads to inflammation and cell survival rather than cell death.
- When cIAP1 is depleted or inhibited, the signalling landscape changes dramatically. Without cIAP1‑mediated ubiquitination, RIPK1 disengages from the TNF receptor complex and forms a cytosolic death‑inducing complex with FADD and caspase‑8. This complex triggers apoptosis. If caspase‑8 activity is compromised, RIPK1 instead cooperates with RIPK3 to initiate necroptosis. Thus, cIAP1 acts as a molecular switch that determines whether TNF signalling promotes survival or death.
- cIAP1 also participates in immune signalling beyond the TNF pathway. It regulates NOD2‑mediated NF‑κB activation through ubiquitination of RIPK2, linking cIAP1 to innate immune responses against bacterial pathogens. Its ability to modulate inflammatory signalling makes cIAP1 relevant in chronic inflammation, autoimmunity and host defence.
- The regulation of cIAP1 is tightly controlled by mitochondrial proteins and therapeutic molecules. Smac/DIABLO, released during apoptosis, binds cIAP1 and promotes its autoubiquitination and degradation. Smac mimetics—small molecules designed to mimic Smac/DIABLO—trigger rapid depletion of cIAP1 and cIAP2, sensitising cells to TNF‑induced apoptosis. This mechanism is being explored in cancer therapy, where cIAP1 overexpression contributes to tumour survival and resistance to treatment.
- In cancer biology, cIAP1 is frequently upregulated, supporting tumour growth, immune evasion and resistance to chemotherapy. Its role in maintaining NF‑κB signalling makes it a key target for therapies aimed at restoring apoptosis in malignant cells. Smac mimetics and cIAP‑specific inhibitors are under active investigation as strategies to destabilise tumour survival pathways.
- In summary, cIAP1 is a critical regulator of apoptosis, ubiquitination and inflammatory signalling. By controlling RIPK1 ubiquitination, cIAP1 determines whether TNF signalling promotes cell survival or triggers apoptosis or necroptosis. Its roles in immunity, inflammation and cancer make cIAP1 a major focus in molecular biology and therapeutic development.
